Drugs / w-3 PUFA
w-3 PUFA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03017001 | Mar 2014 → Jun 2016 | atrial fibrillation | Federal University of Mato Grosso | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | w-3 PUFA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03017001 ↗ |
| Known as | Omega-3 polyunsaturated fatty acids | “Omega-3 polyunsaturated fatty acids (ω-3 PUFA) supplementation is an attractive therapeutic option for patients undergoing open-heart surgery due to their anti-inflammatory and...” PMID 27293143 ↗ May 2016 |
| Known as | ω-3 PUFA | “Omega-3 polyunsaturated fatty acids (ω-3 PUFA) supplementation is an attractive therapeutic option for patients undergoing open-heart surgery due to their anti-inflammatory and...” PMID 27293143 ↗ May 2016 |
| Route | Intravenous | “a dose of intravenous w3-PUFA” NCT03017001 ↗ |